Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Central nervous system–directed antisense therapy ameliorates symptoms in a severe neuromuscular disorder in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
RetractedIdentification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Self-citationMonani, U. R. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1177 · Cited by 954
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Self-citationAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Self-citationLe, T. T., Pham, L. T., Butchbach, M. E. R., Zhang, H. L., Monani, U. R., Coovert, D. D., Gavrilina, T. O., Xing, L., Bassell, G. J., & Burghes, A. H. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi078 · Cited by 598
Hua, Y., Vickers, T. A., Okunola, H. L., Bennett, C. F., & Krainer, A. R. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.01.014 · Cited by 574
Self-citationMcAndrew, P. E., Parsons, D. W., Simard, L. R., Rochette, C., Ray, P. N., Mendell, J. R., Prior, T. W., & Burghes, A. H. M. (1997) · The American Journal of Human Genetics · doi:10.1086/515465 · Cited by 543
The Neurobiology of Childhood Spinal Muscular Atrophy
Crawford, T. O., & Pardo, C. A. (1996) · Neurobiology of Disease · doi:10.1006/nbdi.1996.0010 · Cited by 523
Duque, S., Joussemet, B., Riviere, C., Marais, T., Dubreil, L., Douar, A.-M., Fyfe, J., Moullier, P., Colle, M.-A., & Barkats, M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.71 · Cited by 511
Antisense oligonucleotide therapy for neurodegenerative disease
Smith, R. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25424 · Cited by 506
Neural progenitor cell engraftment corrects lysosomal storage throughout the MRS VII mouse brain
Snyder, E. Y., Taylor, R. M., & Wolfe, J. H. (1995) · Nature · doi:10.1038/374367a0 · Cited by 473
Singh, N. K., Singh, N. N., Androphy, E. J., & Singh, R. N. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1333-1346.2006 · Cited by 454
Baker, B. F., Lot, S. S., Condon, T. P., Cheng-Flournoy, S., Lesnik, E. A., Sasmor, H. M., & Bennett, C. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.11994 · Cited by 371
Self-citationTrichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy
Avila, A. M., Burnett, B. G., Taye, A. A., Gabanella, F., Knight, M. A., Hartenstein, P., Cizman, Z., Di Prospero, N. A., Pellizzoni, L., Fischbeck, K. H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29562 · Cited by 350
Enhancement of SMN2 Exon 7 Inclusion by Antisense Oligonucleotides Targeting the Exon
Hua, Y., Vickers, T. A., Baker, B. F., Bennett, C. F., & Krainer, A. R. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050073 · Cited by 340
Self-citationPassini, M. A., Bu, J., Roskelley, E. M., Richards, A. M., Sardi, S. P., O’Riordan, C. R., Klinger, K. W., Shihabuddin, L. S., & Cheng, S. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41615 · Cited by 292
Self-citationSystemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
Valori, C. F., Ning, K., Wyles, M., Mead, R. J., Grierson, A. J., Shaw, P. J., & Azzouz, M. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000830 · Cited by 285
Rochette, C., Gilbert, N., & Simard, L. (2001) · Human Genetics · doi:10.1007/s004390100473 · Cited by 237
Singh, N. N., Singh, R. N., & Androphy, E. J. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1050 · Cited by 220
SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy
Riessland, M., Ackermann, B., Förster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq023 · Cited by 220
Spinal muscular atrophy: mechanisms and therapeutic strategies
Lorson, C. L., Rindt, H., & Shababi, M. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq147 · Cited by 209
Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy
Azzouz, M., Le, T., Ralph, G. S., Walmsley, L., Monani, U. R., Lee, D. C. P., Wilkes, F., Mitrophanous, K. A., Kingsman, S. M., Burghes, A. H. M., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422922 · Cited by 209
Bevan, A. K., Hutchinson, K. R., Foust, K. D., Braun, L., McGovern, V. L., Schmelzer, L., Ward, J. G., Petruska, J. C., Lucchesi, P. A., Burghes, A. H. M., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq300 · Cited by 209
Congenital heart disease is a feature of severe infantile spinal muscular atrophy
Rudnik-Schöneborn, S., Heller, R., Berg, C., Betzler, C., Grimm, T., Eggermann, T., Eggermann, K., Wirth, R., Wirth, B., & Zerres, K. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2008.057950 · Cited by 202
Phase II Open Label Study of Valproic Acid in Spinal Muscular Atrophy
Swoboda, K. J., Scott, C. B., Reyna, S. P., Prior, T. W., LaSalle, B., Sorenson, S. L., Wood, J., Acsadi, G., Crawford, T. O., Kissel, J. T., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005268 · Cited by 176
Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy
Mercuri, E., Bertini, E., Messina, S., Solari, A., D'Amico, A., Angelozzi, C., Battini, R., Berardinelli, A., Boffi, P., Bruno, C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000249142.82285.d6 · Cited by 172
Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2
Prior, T. W., Swoboda, K. J., Scott, H. D., & Hejmanowski, A. Q. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30251 · Cited by 164
Sustained improvement of spinal muscular atrophy mice treated with trichostatin a plus nutrition
Narver, H. L., Kong, L., Burnett, B. G., Choe, D. W., Bosch‐Marcé, M., Taye, A. A., Eckhaus, M. A., & Sumner, C. J. (2008) · Annals of Neurology · doi:10.1002/ana.21449 · Cited by 152
Quantitation of Phosphorothioate Oligonucleotides in Human Plasma
Leeds, J. M., Graham, M. J., Truong, L., & Cummins, L. L. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0088 · Cited by 143
Corti, S., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Ronchi, D., Saladino, F., Bordoni, A., Fortunato, F., Del Bo, R., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35432 · Cited by 142
Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice
Corti, S. P., Nizzardo, M., Nardini, M., Donadoni, C., Salani, S., Ronchi, D., Simone, C., Falcone, M., Papadimitriou, D. A., Locatelli, F., et al. (2009) · Brain · doi:10.1093/brain/awp318 · Cited by 142
Williams, J. H., Schray, R. C., Patterson, C. A., Ayitey, S. O., Tallent, M. K., & Lutz, G. J. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-09.2009 · Cited by 139
Singh, N. N., Shishimorova, M., Cao, L., Gangwani, L., & Singh, R. N. (2009) · RNA Biology · doi:10.4161/rna.6.3.8723 · Cited by 139
Yu, R. Z., Baker, B. F., Chappell, A. E., Geary, R. S., Cheung, E., & Levin, A. A. (2002) · Analytical Biochemistry · doi:10.1006/abio.2002.5576 · Cited by 138
Abnormal motor phenotype in the SMNΔ7 mouse model of spinal muscular atrophy
Butchbach, M. E. R., Edwards, J. D., & Burghes, A. H. M. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.04.009 · Cited by 122
Butchbach, M. E. R., Singh, J., Þorsteinsdóttir, M., Saieva, L., Slominski, E., Thurmond, J., Andrésson, T., Zhang, J., Edwards, J. D., Simard, L. R., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp510 · Cited by 119
Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice
Tsai, L., Tsai, M., Ting, C.-H., & Li, H. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0388-1 · Cited by 117
Baughan, T. D., Dickson, A., Osman, E. Y., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp076 · Cited by 115
Garbes, L., Rießland, M., Hölker, I., Heller, R., Hauke, J., Tränkle, C., Coras, R., Blümcke, I., Hahnen, E., & Wirth, B. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp313 · Cited by 110
Therapeutics development for spinal muscular atrophy
Sumner, C. J. (2006) · NeuroRx · doi:10.1016/j.nurx.2006.01.010 · Cited by 108
Tetracyclines That Promote SMN2 Exon 7 Splicing as Therapeutics for Spinal Muscular Atrophy
Hastings, M. L., Berniac, J., Liu, Y. H., Abato, P., Jodelka, F. M., Barthel, L., Kumar, S., Dudley, C., Nelson, M. L., Larson, K. C., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000208 · Cited by 97
Self-citationTrans-Splicing-Mediated Improvement in a Severe Mouse Model of Spinal Muscular Atrophy
Coady, T. H., & Lorson, C. L. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4489-09.2010 · Cited by 95
Molecular Mechanisms of Spinal Muscular Atrophy
Sumner, C. J. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305787 · Cited by 94
Mattis, V. B., Ebert, A. D., Fosso, M. Y., Chang, C.-W., & Lorson, C. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp333 · Cited by 94
Medical Considerations of Long-Term Survival of Werdnig–Hoffmann Disease
Bach, J. R. (2007) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e31804b1d66 · Cited by 88
Oskoui, M., & Kaufmann, P. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.08.007 · Cited by 80
Cited by
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706198 · Cited by 2,381
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
Mercuri, E., Darras, B. T., Chiriboga, C. A., Day, J. W., Campbell, C., Connolly, A. M., Iannaccone, S. T., Kirschner, J., Kuntz, N. L., Saito, K., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710504 · Cited by 1,433
Self-citationMechanisms and Regulation of Alternative Pre-mRNA Splicing
Lee, Y., & Rio, D. C. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034316 · Cited by 1,291
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Self-citationOvercoming cellular barriers for RNA therapeutics
Dowdy, S. F. (2017) · Nature Biotechnology · doi:10.1038/nbt.3802 · Cited by 1,139
Metadata
- Authors
- Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., Kaye, E. M., Shihabuddin, L. S., Krainer, A. R., Bennett, C. F., & Cheng, S. H.
- Venue
- Science Translational Medicine
- Published
- 2011-03-02
- Volume
- 3
- Issue
- 72
- Pages
- 72ra18-72ra18
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2115222513
- Cited by
- 547
- References
- 49
- FWCI
- 17.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.